EDN1 and Achalasia: Our data suggest that TGFβ and ET‐1 blockade might represent a potential future strategy to treat muscle fibrosis, particularly in the pharyngeal muscles of patients suffering from OPMD and achalasia but also in other muscle pathologies involving fibrosis.